Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia: Annals of the New York Academy of Sciences

Annals of the New York Academy of Sciences

Volumn 1193, Issue , 2010, Pages 146-152

  Adorini, Luciano ^a   Penna, Giuseppe ^a   Fibbi, Benedetta ^b   Maggi, Mario ^b  

^a INTERCEPT PHARMACEUTICALS   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antigen presenting cells; Benign prostatic hyperplasia; Chronic prostatic inflammation; Chronic prostatitis chronic pelvic pain syndrome

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; BXL 353; CALCITRIOL; CARBOPLATIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYPROTERONE ACETATE; DEXAMETHASONE; DOCETAXEL; ELOCALCITOL; ESTRAMUSTINE; FINASTERIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR AGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; BLADDER EPITHELIUM; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HYPERPARATHYROIDISM; IMMUNOMODULATION; INFLAMMATORY INFILTRATE; LOWER URINARY TRACT SYMPTOM; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOPOROSIS; OVERACTIVE BLADDER; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN EXPRESSION; PROTEIN TARGETING; PSORIASIS; SIGNAL TRANSDUCTION; TACHYCARDIA; VITAMIN METABOLISM; XEROSTOMIA;

EID: 77951249848     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05299.x     Document Type: Conference Paper

References (45)

1. Roehrborn, C.G. 2008. Pathology of benign prostatic hyperplasia. Int. J. Impot Res. 20(Suppl 3): S11-S18.
2. McVary, K.T. 2006. BPH: epidemiology and comorbidities. Am. J. Manag. Care 12: S122-S128.
3. Andersson, K.E. & A. Arner. 2004. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol. Rev. 84: 935-986.
4. Nickel, J.C. 2008. Inflammation and benign prostatic hyperplasia. Urol. Clin. North Am. 35: 109-115; vii.
5. Lee, K.L. & D.M. Peehl. 2004. Molecular and cellular pathogenesis of benignprostatic hyperplasia. J.Urol. 172: 1784-1791.
6. Nickel, J.C., M. Elhilali & G. Vallancien. 2005. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU Int. 95: 571-574.
7. Roehrborn, C.G. 2008. BPH progression: concept and key learning fromMTOPS,ALTESS,COMBAT, andALFONE. BJU Int. 101(Suppl 3): 17-21.
8. Greco, K.A. & K.T. McVary. 2008. The role of combination medical therapy in benign prostatic hyperplasia. Int. J. Impot. Res. 20(Suppl 3): S33-S43.
9. Adorini, L. & G. Penna. 2008. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 4: 404-412.
10. Holick,M.F. 2007. VitaminDdeficiency. N. Engl. J.Med. 357: 266-281.
11. Crescioli, C., M. Maggi, M. Luconi, et al. 2002. Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in humanprostate cancer cells. Prostate. 50: 15-26.
12. Crescioli, C., A. Morelli, L. Adorini, et al. 2005. Human bladder as a novel target for vitamin D receptor ligands. J. Clin. Endocrinol. Metab. 90: 962-972.
13. Peehl, D.M., R.J. Skowronski, G.K. Leung, et al. 1994. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of humanprostatic cells. CancerRes. 54: 805-810.
14. Mikhak, B., D.J. Hunter, D. Spiegelman, et al. 2007. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate. 67: 911-923.
15. Krishnan, A.V.,D.M. Peehl&D. Feldman. 2003. The role of vitamin D in prostate cancer. Recent Results Cancer Res. 164: 205-221.
16. Konety, B.R., J.P. Lavelle, G. Pirtskalaishvili, et al. 2001. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J. Urol. 165: 253-258.
17. Schwartz, G.G. 2005. Vitamin D and the epidemiology of prostate cancer. Semin Dial. 18: 276-289.
18. Schwartz, G.G., L.W. Whitlatch, T.C. Chen, et al. 1998. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 7: 391-395.
19. Chen, T.C., L. Wang, L.W. Whitlatch, et al. 2003. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J. Cell. Biochem. 88: 315-322.
20. Harzstark, A.L. & C.J. Ryan. 2008. Novel therapeutic strategies in development for prostate cancer. Expert Opin. Investig. Drugs 17: 13-22.
21. Beer, T.M.,C.W.Ryan, P.M.Venner, et al. 2008. Intermittent chemotherapy in patientswith metastatic androgenindependent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 112: 326-330.
22. Maggi, M., C. Crescioli, A. Morelli, et al. 2006. Preclinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). J. Endocrinol. Invest. 29: 665-674.
23. Crescioli, C., P. Ferruzzi, A. Caporali, et al. 2004. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol. 150: 591-603.
24. Adorini, L., G. Penna, S. Amuchastegui, et al. 2007. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J. Steroid Biochem. Mol. Biol. 103: 689-693.
25. Morelli, A., L. Vignozzi, S. Filippi, et al. 2007. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate. 67: 234-247.
26. Peters, S.L., M. Schmidt & M.C. Michel. 2006. Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol. Sci. 27: 492-497.
27. Morelli, A., R. Squecco, P. Failli, et al. 2008. The vitamin Dreceptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder.Am. J. Physiol. Cell Physiol. 294: C1206-C1214.
28. Schroder,A., E.Colli, M.Maggi&K.W.Andersson. 2006. Effects of a vitamin D(3) analogue in a rat model of bladder outlet obstruction. BJU Int. 98: 637-642.
29. Kramer, G., D. Mitteregger & M. Marberger. 2007. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur. Urol. 51: 1202-1216.
30. Sciarra, A., G. Mariotti, S. Salciccia, et al. 2008. Prostate growth and inflammation. J. Steroid Biochem. Mol. Biol. 108: 254-260.
31. Roehrborn, C.G. 2006. Definition of at-risk patients: baseline variables. BJU Int. 97(Suppl 2): 7-11; discussion 21-112
32. Nickel, J.C., C.G. Roehrborn, M.P. O'Leary, et al. 2008. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur. Urol. 54: 1379-1384.
33. Steiner, G.E.,U. Stix, A.Handisurya, et al. 2003.Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab. Invest. 83: 1131-1146.
34. Handisurya, A., G.E. Steiner, U. Stix, et al. 2001. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate. 49: 251-262.
35. Steiner, G.E., M.E. Newman, D. Paikl, et al. 2003. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 56: 171-182.
36. Penna, G., N. Mondaini, S. Amuchastegui, et al. 2007. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin-8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur. Urol. 51: 524-533.
37. Prakash, K., G. Pirozzi, M. Elashoff, et al. 2002. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc. Natl. Acad. Sci. USA. 99: 7598-7603.
38. Colli, E., P. Rigatti, F. Montorsi, et al. 2006. BXL628, a novel vitamin D3 analog arrests prostate growth in patientswith benign prostatic hyperplasia: a randomized clinical trial. Eur. Urol. 49: 82-86.
39. Penna, G., S. Amuchastegui, C. Cossetti, et al. 2006. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J. Immunol. 177: 8504-8511.
40. Penna, G., B. Fibbi, S. Amuchastegui, et al. 2009. The vitamin D receptor agonist elocalcitol inhibits IL-8- dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 69: 480-493.
41. Segain, J.P., D. Raingeard de la Bietiere, V. Sauzeau, et al. 2003. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology. 124: 1180-1187.
42. Montaner, S., R. Perona, L. Saniger & J.C. Lacal. 1998. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J. Biol. Chem. 273: 12779-12785.
43. Zhao, D., S. Kuhnt-Moore, H. Zeng, et al. 2003. Neurotensin stimulates IL-8 expression in humancolonic epithelial cells through Rho GTPase-mediated NF-kappa B pathways.Am. J. Physiol.Cell Physiol. 284: C1397-C1404.
44. Rivero, V.E., C. Cailleau, M. Depiante-Depaoli, et al. 1998. Non-obese diabetic (NOD) mice are genetically susceptible to experimental autoimmune prostatitis (EAP). J. Autoimmun. 11: 603-610.
45. Penna, G., B. Fibbi, S. Amuchastegui, et al. 2009.Human benignprostatichyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J. Immunol. 182: 4056-4064.